We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (METRO)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01508416
First Posted: January 12, 2012
Last Update Posted: July 28, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Institut de Cancérologie de la Loire
Groupe de Recherche sur la Thrombose
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Saint Etienne
December 15, 2011
January 12, 2012
July 28, 2015
January 2012
December 2014   (Final data collection date for primary outcome measure)
  • change from baseline in Thrombin generation measure [ Time Frame: day 21 ]
    change from baseline in Thrombin generation measure
  • change from baseline in Thrombin generation measure [ Time Frame: day 42 ]
    change from baseline in Thrombin generation measure
  • change from baseline in Thrombin generation measure [ Time Frame: day 63 ]
    change from baseline in Thrombin generation measure
  • change from baseline in Thrombin generation measure [ Time Frame: day 0 ]
    change from baseline in Thrombin generation measure
Same as current
Complete list of historical versions of study NCT01508416 on ClinicalTrials.gov Archive Site
  • image-confirmed venous thromboembolic events [ Time Frame: day 63 ]
    Estimate the incidence of venous thromboembolic events until day 63
  • change from baseline in TFPI resistance measure [ Time Frame: day 21 ]
    change from baseline in TFPI resistance measure
  • change from baseline in acquired protein S deficiency measure [ Time Frame: day 21 ]
    change from baseline in acquired protein S deficiency measure
  • change from baseline in TFPI resistance measure [ Time Frame: day 42 ]
    change from baseline in TFPI resistance measure
  • change from baseline in TFPI resistance measure [ Time Frame: day 63 ]
    change from baseline in TFPI resistance measure
  • change from baseline in acquired protein S deficiency measure [ Time Frame: day 42 ]
    change from baseline in acquired protein S deficiency measure
  • change from baseline in acquired protein S deficiency measure [ Time Frame: day 63 ]
    change from baseline in acquired protein S deficiency measure
  • change from baseline in TFPI resistance measure [ Time Frame: day 0 ]
    change from baseline in TFPI resistance measure
  • change from baseline in acquired protein S deficiency measure [ Time Frame: day 0 ]
    change from baseline in acquired protein S deficiency measure
Same as current
Not Provided
Not Provided
 
Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma
Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma: a Multicentric Study

Patients with Multiple Myeloma (MM) are at increased risk of venous thromboembolic event, especially in newly diagnosed patients and during induction treatment with thalidomide in combination with dexamethasone. This association was mainly heightened during the 3 first months of chemotherapy.

Several coagulation abnormalities have been described. Laboratory tests measuring the overall thrombophilic tendency might be useful to assess thrombosis risk.

The aim of this study is to compare thrombin generation by calibrated automated thrombogram during the 3 first cycles of chemotherapy in patients with newly diagnosed MM.

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
whole blood and serum
Non-Probability Sample
Patients with newly diagnosed Multiple Myeloma required chemotherapy
Multiple Myeloma
Not Provided
Patients with Multiple Myeloma
Patients with newly diagnosed Multiple Myeloma required chemotherapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
71
June 2015
December 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Inscription to medical assurance
  • Patients who gave their written consent
  • Patients with newly diagnosed Multiple Myeloma required chemotherapy

Exclusion Criteria:

  • Patients with renal failure who need to undergo hemodialysis
  • Patients with indication for curative anticoagulant therapy
  • Patient with 3 month follow-up not possible
  • Patient with life expectancy < 6 month
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT01508416
1108178
2011- A01529-32 ( Other Identifier: Afssaps )
No
Not Provided
Not Provided
Centre Hospitalier Universitaire de Saint Etienne
Centre Hospitalier Universitaire de Saint Etienne
  • Institut de Cancérologie de la Loire
  • Groupe de Recherche sur la Thrombose
Principal Investigator: Bernard TARDY, MD-PhD CHU de Saint-Etienne - CIC-EC (CIE3)
Centre Hospitalier Universitaire de Saint Etienne
July 2015